



## Target and Im-Oncology Therapeutic Approaches for Lung Cancer

Guest Editors:

**Prof. Dr. Shun Lu**

Department of Oncology,  
Shanghai Chest Hospital,  
Shanghai Jiao Tong University,  
Shanghai 200030, China

**Prof. Dr. Yongfeng Yu**

Shanghai Lung Cancer Center,  
Shanghai Chest Hospital,  
Shanghai Jiao Tong University,  
Shanghai 200030, China

Deadline for manuscript  
submissions:

**closed (25 April 2023)**

### Message from the Guest Editors

Dear Colleagues,

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1.8 million people are diagnosed with lung cancer, and 1.6 million people die as a result of the disease. Five-year survival rates vary from 4 to 17% depending on stage and regional differences.

Recognition that lung cancer is primarily a disease of the genome has fueled recent focus on the development of more personalized or precision treatments based on genomic information. Lung cancer can thus be subdivided into clinically relevant molecular subsets, including EGFR, ALK, ROS1, HER2, BRAF, KRAS, RET, MET, and so on. Targeted therapy could lead to substantial outcome improvements. Meanwhile, unprecedented advances have been made in lung cancer treatment with the use of immunotherapy. However, limited responses to a subset of patients, drug resistance, and treatment-related adverse events are still unsolved. The scope of this Special Issue is to provide an overview of recent advances in the field of targeted therapy and immunotherapy for lung cancer. Therefore, researchers in this field are encouraged to submit an original article or review to this Special Issue.





an Open Access Journal by MDPI

## Editors-in-Chief

**Prof. Dr. Emmanuel Andrès**

Internal Medicine Department,  
University Hospital Strasbourg,  
67081 Strasbourg, France

**Prof. Dr. Kent Doi**

Department of Emergency and  
Critical Care Medicine, The  
University of Tokyo, Tokyo, Japan

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

## Contact Us

---

*Journal of Clinical Medicine* Editorial  
Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jcm](http://mdpi.com/journal/jcm)  
[jcm@mdpi.com](mailto:jcm@mdpi.com)  
[X@JCM\\_MDPI](https://twitter.com/JCM_MDPI)